Data from Exploratory Analysis Show Merck’s KEYTRUDA® (pembrolizumab) Improved Overall Survival as Monotherapy for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Regardless of KRAS Mutational Status
New Findings from Phase 3 KEYNOTE-042 Study Were Presented Today at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2019
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that KEYTRUDA, Merck’s anti-PD-1 therapy, showed improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) as monotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC) whose tumors expressed PD-L1 (tumor proportion score [TPS] ≥1%), regardless of KRAS mutational status.
Media:
Pamela Eisele
(267) 305-3558
Justine Moore
(347) 281-3754
Investors:
Peter Dannenbaum
(908) 740-1037
Michael DeCarbo
(908) 740-1807
